Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
about
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromesCurrent status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsHigh residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistancePlant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonistsExpert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyTicagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An UpdateCardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patientsAntiplatelet drug interactions with proton pump inhibitorsLower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO studyAnti-platelet therapy: ADP receptor antagonists.Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.Critical appraisal of ticagrelor in the management of acute coronary syndromeEfficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis.Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.The use of oral suspension and rationally prescribing alternatives may be supplemental to the implementation of clopidogrel new algorithm comprising CYP2C19 pharmacogenetics and drug interactions.Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorRelationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patientsEfficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome."Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.Ticagrelor: from concept to clinical evaluation.Ticagrelor: a review of its use in the management of acute coronary syndromes.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Antiplatelet options for secondary prevention in acute coronary syndromes.Clopidogrel and PPI interaction: clinically relevant or not?Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.P2Y12 platelet inhibition in clinical practice.Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment.Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines.Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.PAR-1 antagonists: current state of evidence.Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.Safety profile and bleeding risk of ticagrelor compared with clopidogrel.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.Assessing post-treatment platelet reactivity: a focus on patient selection and setting.
P2860
Q24631111-0473B699-DDA7-48C7-B833-97523DFEA890Q26771106-C65D7682-2AA0-4E60-9C89-17C97A3E7FB2Q26824850-39338C11-D6DB-4C74-8DC1-2F6F95C6C4BAQ26861282-B196A262-0BD6-4971-9C2F-0568C6F10921Q26998331-E9A26AD2-8A61-4906-9C5B-21149D5AEED6Q27006031-BA31DBDE-1F10-4476-A4F3-B842C134432AQ30821177-BEA881A8-BA28-433B-9C73-5B8C91CF2EF7Q33646807-6940E44F-6329-4223-8446-4141F2C26A5EQ33948811-881A556D-AD84-4D04-B035-48FB2127EB3EQ34456208-B45C16AD-1F94-4CB5-A9E7-D44E722798D1Q35278165-C4669B8F-9E49-4C1F-9239-820EE002A5DBQ35569714-23CB2985-DD16-49CF-89C1-786DB8FE91F3Q35660767-E85EE7DA-F3E9-44CE-9601-65B5E236FE69Q36237726-8F852882-8CC6-46E5-905B-D808EBF1AFFCQ36330189-B0D1F7A1-7E69-4232-9F2B-264CC09903DBQ36658196-D80D121F-B1B6-4CAB-AEA1-0B5C4E3C235FQ36807413-31AB80D9-AFAC-4B47-9EF8-C869E710A7C5Q37039218-CDC8C467-199E-468C-9B36-226CAD0C269BQ37103506-A82C1E7C-9A78-459E-B53C-FB3D8DF20F76Q37561275-89782170-FB06-4777-8A9C-1A76FDF0FD46Q37841570-CC5A6502-62BE-41E6-AEC4-008817784C01Q37875063-F2E73A69-CFD9-41B5-AEDC-2182ECC83800Q37908891-A08349C2-9ECF-4424-8F29-E6AF079ED731Q37953465-9DBDB36A-FF23-488F-83CB-2E1901516D41Q37957037-B38FABE1-7166-4C0C-947D-E3CB0928CE1EQ37959155-C7FAE801-27C8-4902-B6B6-A662AFFD2D02Q37969927-6324077D-61F8-4291-A77E-2FEFD6068A41Q37984773-DB90C4F4-9E57-4E03-8CEF-8A1ECD409785Q37990848-5C426005-7B52-455C-AAD3-55DAE4ED989DQ37998114-6F45E97D-2FEF-48B8-89EE-F79A6FF01DEAQ38001453-AB3D75EC-F19F-4236-AA93-77A8BAEE87A5Q38014344-B51C4583-7032-4CAF-B350-D2E5AD58EC15Q38018674-3723F4D5-0FF8-4F6B-A3DD-78BA520F460BQ38032614-8E0E6C43-5EF3-4C76-951C-06016D9FD803Q38040816-95B33D81-ADE1-4B0A-B250-E438F987DB10Q38053481-7F9162F3-1139-4BBE-BBA8-091338AA3BFDQ38065124-508AD887-392E-4665-AAAE-4A7DDBF3CCB0Q38094070-CE88AA71-EA12-4E52-B57A-AC5576E498C3Q38132252-378A2DB7-B4F7-452A-AAAD-A50DCDB4067EQ38132923-B04FADB0-F3A3-407F-917A-F874B17E4A5A
P2860
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Inhibitory effects of ticagrel ...... t Outcomes) PLATELET substudy.
@en
Inhibitory effects of ticagrel ...... coronary syndromes: the PLATO
@nl
type
label
Inhibitory effects of ticagrel ...... t Outcomes) PLATELET substudy.
@en
Inhibitory effects of ticagrel ...... coronary syndromes: the PLATO
@nl
prefLabel
Inhibitory effects of ticagrel ...... t Outcomes) PLATELET substudy.
@en
Inhibitory effects of ticagrel ...... coronary syndromes: the PLATO
@nl
P2093
P50
P1476
Inhibitory effects of ticagrel ...... t Outcomes) PLATELET substudy.
@en
P2093
Bhaloo Desai
Christopher P Cannon
Dominick J Angiolillo
Richard C Becker
Rosemary Ecob
Shankar B Patil
Steen Husted
P304
P356
10.1016/J.JACC.2010.03.100
P407
P577
2010-10-01T00:00:00Z